Reprogramming TAMs from M2 to M1 using cytokines or inhibitors can enhance anti-tumor immunity. Targeting PD-L1 on TAMs or disrupting recruitment pathways (e.g., CCL2-CCR2) is under investigation. Here, CCL2 is linked to neoplasm.